住院成人使用布洛芬与急性肾损伤
该回顾性活性对照队列研究纳入2004年1月1日至2017年6月30日期间在费城3家医院住院的78 656例成人患者,比较使用布洛芬(n=6313)与羟考酮(n=72 343)至少24小时治疗急性疼痛者的急性肾损伤风险。经平衡权重调整后,布洛芬组任何急性肾损伤发生率更高(IRR 1.22,95%CI 1.09-1.38),严重急性肾损伤(IRR 1.36,95%CI 1.08-1.72)和肾脏替代治疗(IRR 3.29,95%CI 1.35-8.03)发生率也更高。术后患者(IRR 1.70 vs 1.12)和重症患者(IRR 1.65 vs 1.16)中IRR更大;低危患者(非重症、非术后、年龄<60岁且无肾功能不全)中布洛芬与急性肾损伤风险升高无关(IRR 0.94,95%CI 0.75-1.18)。
要点
- 住院成人使用布洛芬至少24小时与任何急性肾损伤发生率升高相关(IRR 1.22,95%CI 1.09-1.38),严重急性肾损伤IRR 1.36(95%CI 1.08-1.72),肾脏替代治疗IRR 3.29(95%CI 1.35-8.03)。
- 术后患者使用布洛芬的急性肾损伤IRR为1.70(95%CI 1.28-2.27),非术后患者为1.12(95%CI 0.98-1.28)。
- 重症患者使用布洛芬的急性肾损伤IRR为1.65(95%CI 1.29-2.11),非重症患者为1.16(95%CI 1.02-1.33)。
- 低危患者(非重症、非术后、年龄<60岁且无肾功能不全)中布洛芬与急性肾损伤风险升高无关(IRR 0.94,95%CI 0.75-1.18)。
- 作者认为低危患者或许可以安全使用布洛芬,但这类患者常被处方羟考酮。
适用人群与场景
- 住院成人患者(年龄≥18岁),无终末期肾病且无NSAID治疗禁忌证,入院时间2004年1月1日至2017年6月30日,来自费城3家医院的学术健康系统。
- 低危亚组定义为非重症、非术后、年龄<60岁且无肾功能不全的患者(布洛芬n=2966,羟考酮n=20440)。
研究设计与关键结果
- 研究类型为回顾性活性对照队列研究,纳入78 656例患者(中位年龄59岁,IQR 47-69岁;女性38 092例,占48%),布洛芬组n=6313,羟考酮组n=72 343,随访至治疗结束后48小时、出院或满14天(以先发生者为准)。
- 随访期间共发生4799例急性肾损伤事件(79%为1期),总随访270 472天,发生率为17.7例/1000天。
- 经平衡权重调整基线差异后,布洛芬组任何急性肾损伤发生率更高(IRR 1.22,95%CI 1.09-1.38),严重急性肾损伤(IRR 1.36,95%CI 1.08-1.72)和肾脏替代治疗(IRR 3.29,95%CI 1.35-8.03)发生率也更高。
- 术后患者IRR为1.70(95%CI 1.28-2.27),非术后患者为1.12(95%CI 0.98-1.28)。
- 重症患者IRR为1.65(95%CI 1.29-2.11),非重症患者为1.16(95%CI 1.02-1.33)。
- 低危患者中布洛芬与急性肾损伤风险升高无关(IRR 0.94,95%CI 0.75-1.18)。
证据类型、等级与局限
- 证据类型:回顾性活性对照队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,住院患者使用布洛芬与急性肾损伤和肾脏替代治疗发生率升高相关,但超额风险集中于高危患者;低危患者或许可以安全使用布洛芬,但这类患者常被处方羟考酮。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Although nonsteroidal anti-inflammatory drugs (NSAIDs) are the most effective nonopioid analgesics for acute pain, they may be underused in the inpatient setting due to uncertainty regarding the risk of acute kidney injury (AKI). Whether inpatient exposure to NSAIDs, such as ibuprofen, substantially increases AKI risk and how ibuprofen-associated AKI varies across patient subgroups remain unknown.
OBJECTIVE: To determine whether ibuprofen use is associated with AKI in hospitalized patients and whether the finding varies across AKI risk factor subgroups.
DESIGN, SETTING, AND PARTICIPANTS: A retrospective active-comparator cohort study of hospitalized patients (aged ≥18 years) without end-stage kidney disease or contraindications to NSAID treatment admitted from January 1, 2004, to June 30, 2017, in a large academic health system including 3 hospitals in Philadelphia, Pennsylvania, with follow-up until 48 hours after treatment end, hospital discharge, or 14 days elapsed, whichever occurred first. Analyses were conducted from March 2023 through August 2026.
EXPOSURES: At least 24 hours of treatment with ibuprofen or oxycodone for acute pain.
MAIN OUTCOMES AND MEASURES: The primary outcome was AKI, defined by changes in serum creatinine and incident kidney replacement therapy (KRT). Balancing weights were used to adjust for baseline covariates and weighted Poisson regression used to estimate incidence rate ratios (IRRs) and 95% CIs.
RESULTS: This study included 78 656 patients (median age, 59 [IQR, 47-69] years; 38 092 females [48%]) treated with ibuprofen (n = 6313) or oxycodone (n = 72 343). There were 4799 AKI events (79% stage 1) during 270 472 days of follow-up (17.7 events per 1000 days). After adjustment for baseline differences, patients treated with ibuprofen had a higher rate of any AKI (IRR, 1.22; 95% CI, 1.09-1.38), severe AKI (IRR, 1.36; 95% CI, 1.08-1.72), and KRT (IRR, 3.29; 95% CI, 1.35-8.03). IRRs were greater in postoperative (IRR, 1.70 [95% CI, 1.28-2.27] vs 1.12 [95% CI, 0.98-1.28]) and critically ill (IRR, 1.65 [95% CI, 1.29-2.11] vs 1.16 [95% CI, 1.02-1.33]) patients. In patients at low risk (those non-critically ill, nonpostoperative, aged <60 years without kidney dysfunction; ibuprofen, n = 2966; oxycodone, n = 20 440), ibuprofen was not associated with higher AKI risk (IRR, 0.94; 95% CI, 0.75-1.18).
CONCLUSIONS AND RELEVANCE: This study in an inpatient cohort found that ibuprofen was associated with higher rates of AKI and KRT, but this excess risk was concentrated in patients at high risk. Patients at low risk may be able to receive ibuprofen safely yet were often prescribed oxycodone.
参考来源
- Thelen HE, Keele LJ, Brotman C, et al. Ibuprofen Use and Acute Kidney Injury Among Adults Admitted to the Hospital. JAMA Netw Open. 2026. PMID: 43007674. doi:10.1001/jamanetworkopen.2026.42745
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。